BrightFocus-Funded Research Shows Parkinson’s Drug Could be Repurposed to Save Sight of Millions
In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.
The findings, published in the American Journal of Medicine, are a groundbreaking effort in the fight against age-related macular degeneration (AMD), which affects as many as 11 million Americans. AMD hinders central vision, and even when it does not lead to blindness it can severely reduce the ability to read, drive, and recognize faces.
In the study, supported in part by BrightFocus Foundation, researchers discovered a biological connection between darker pigmented eyes, that are known to be resistant to AMD, and increased levels of a chemical called L-DOPA in those eyes. Since L-DOPA is frequently prescribed for Parkinson’s patients, the researchers wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. By combing through massive databases of medical chart data, they reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
“Rather than looking at what might cause AMD, we instead wondered why certain people are protected from AMD. This approach had never been done before,” says senior author Brian McKay of the University of Arizona.
The research findings are based off an analysis of the medical records of 37,000 patients at the Marshfield Clinic in Wisconsin. Because the average age of those given L-DOPA is 67, while the average age of AMD diagnosis is 71, scientists were able to effectively track patterns. These major findings were then confirmed by reviewing a data set of 87 million patients. In this large scale data set, L-DOPA also delayed or prevented AMD from progressing to its “wet” form, the most devastating form of the disease.
“This exciting breakthrough shows the power of scientific discovery to give hope to millions of people across the nation and the world. Their methodology is a reminder that ‘big data’ is not a buzzword—it is a bold and innovative new approach to science,” said BrightFocus president and CEO Stacy Pagos Haller.
The Latest on: L-DOPA
via Google News
The Latest on: L-DOPA
- Neuropathy in Parkinson’s Disease May Be Related to L-Dopa Exposureon May 6, 2020 at 5:00 pm
The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...
- Research reveals mechanism underlying Parkinson's dyskinesiaon May 3, 2020 at 6:57 am
Many people with Parkinson's disease eventually develop debilitating movements called dyskinesia, a side effect of their much-needed dopamine replacement medication.
- Parkinson's dyskinesia mechanism explainedon May 1, 2020 at 1:34 pm
Many people with Parkinson's disease eventually develop debilitating movements called dyskinesia, a side effect of their much-needed dopamine replacement medication. The mechanism underlying this ...
- Gene Therapies for Parkinson’s Diseaseon May 1, 2020 at 5:35 am
Parkinson's disease is a progressive neurodegenerative disease that is estimated to affect 1-2% per 1000 people 60 years or older at any given time.
- Parkinson's dyskinesia mechanism explainedon April 30, 2020 at 5:00 pm
This boost in RasGRP1 produces a cascade of effects which lead to abnormal, involuntary movements known as LID, or L-DOPA-induced dyskinesia, says co-lead author Srinivasa Subramaniam, PhD ...
- RasGRP1 is a causal factor in the developmenton April 30, 2020 at 5:00 pm
Fig. 2. RasGRP1 mediates l-DOPA–induced mTOR, ERK, and GluR1 signaling in the striatum. (A) Western blot analysis of intact and 6-OHDA–lesioned striatum of WT and RasGRP1 KO mice after l-DOPA ...
- FDA Approves Neurocrine Biosciences' Parkinson's Drugon April 27, 2020 at 2:45 pm
Neurocrine Biosciences (NASDAQ:NBIX) announced Monday that the Food and Drug Administration (FDA) has approved Ongentys (opicapone), a daily pill for Parkinson's disease. Ongentys is an add-on ...
- FDA Approves Neurocrine Biosciences' Parkinson's Drugon April 27, 2020 at 10:58 am
Ongentys is an add-on treatment for Parkinson's patients who are currently taking the main first-line treatment, levodopa (L-Dopa), combined with carbidopa to moderate side effects. As the disease ...
- L-Dopa Capsule Side Effects by Likelihood and Severityon September 15, 2014 at 6:29 am
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except ...
- Does L-Dopa Capsule Interact with other Medications?on November 5, 2013 at 6:39 am
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Selected from data included with permission and ...
via Bing News